Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Arja Rydin, PhD Candidate at Amsterdam UMC | Image Credit: LinkedIn

Depressive symptoms such as low energy have been linked to 

, and inflammation through hypersomnia and appetite/weight alterations.

Prior research has highlighted the association between depression and several diseases, including 

 and diabetes. Additionally, a bidirectional association has been noted between depression and cardiometabolic disorder (CMD). Inflammatory and metabolic alterations, along with other mechanisms, may be important in this relationship.

“The current work extends on former work by incorporating repeated measurements of individual symptoms, markers of inflammation and cardiometabolic syndrome, and disease outcomes in a novel framework of Bayesian network analysis,” Arja Rydin, a PhD candidate in the department of psychiatry at Amsterdam UMC, and colleagues wrote. “Overall, our analytical approach allowed us to not only take into account biological, lifestyle, and psychiatric variables, but also the dimension of time, deepening the understanding of the comorbidity of depression, immune-metabolic dysregulations, and cardiometabolic diseases.”

Investigators utilized data from the Netherlands Study of Depression and Anxiety (NESDA), an ongoing longitudinal cohort study of depressive and anxiety disorders. NESDA is a naturalistic, multisite, case-control cohort study. The NESDA team conducted an initial baseline face-to-face assessment, followed by planned follow-up data collection waves after 1, 2, 4, 6, and 9 years. The initial assessments lasted 3-4 hours and consisted of self-report questionnaires, a medical examination, cognitive/emotional computer tasks, and biobanking with stored blood sampling.

In total, investigators included 2981 participants to NESDA – of these, 2329 exhibited a lifetime diagnosis of depressive and/or anxiety disorders, while 652 did not. Mean age at baseline was 41.9 years (standard deviation [SD] 13). However, during the 9-year follow-up, investigators also enrolled 367 siblings from 256 participants with lifetime anxiety and/or depressive disorders, which brought the total participants to 3348. This addition allowed for examination of the family context in the development of depression and anxiety.

Rydin and colleagues filtered the NESDA data to select 1059 patients with lifetime diagnoses of major depressive disorder (MDD) and a mean age of 42.4 +/- 12.5 years old. Depressive symptoms were highlighted via self-report questionnaires from the Inventory of Depressive Symptomatology. Additionally, the team examined pathophysiological data on metabolic syndrome components and inflammatory markers, as well as CMD.

Ultimately, the investigators found a chain of energy-related depressive symptoms, namely increases in appetite, weight oscillations, and hypersomnia, connecting to waist circumference and thus diabetes. Waist circumference was noted as most influential on the system, as sensitivity analyses confirmed.

Investigators noted prior research indicating associations between depression and increased waist circumference. Additionally, increases in abdominal adiposity have been recorded in patients with atypical depression, according to other studies. However, the utilization of a Bayesian network analysis in this particular study allowed investigators to locate directed associations without imposing a direction as a starting point. This, in turn, allows for the measurement of the quantitative importance of variables.

Rydin and colleagues suggest future research to further investigate these associations. They encourage applying a similar framework to other comorbidities, as well as running a similar analysis with a dataset with CMD cases.

“Energy-related dysregulations, both regarding depressive symptoms and physiological characteristics, prove to be of importance in this longitudinal approach,” Rydin and colleagues wrote. “Future work should focus on this aspect of depression and provide more mechanistic insights into the MDD-CDD comorbidity. Intervention strategies could benefit by targeting the factor of abdominal adiposity.”

Rydin AO, Milaneschi Y, Lamers F, et al. Trajectories of depressive symptoms, metabolic syndrome, inflammation, and cardiometabolic diseases: A longitudinal Bayesian network approach. 

Penninx BWJH, Eikelenboom M, Giltay EJ, et al. Cohort profile of the longitudinal Netherlands study of depression and anxiety (NESDA) on etiology, course and consequences of depressive and anxiety disorders. 

Articles

Depressive symptoms, such as low energy, are linked to diabetes, dyslipidemia, and inflammation through mechanisms like hypersomnia and appetite changes. A bidirectional relationship exists between depression and cardiometabolic disorders (CMD), influenced by inflammatory and metabolic alterations. Using data from the Netherlands Study of Depression and Anxiety (NESDA), researchers employed Bayesian network analysis to explore these associations. They identified energy-related depressive symptoms, such as increased appetite and hypersomnia, as connected to waist circumference and diabetes. Future research should focus on abdominal adiposity's role in depression-CMD comorbidity.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Depressive Symptoms May Be Associated with Diabetes and Dyslipidemia

2025 Fall Clinical Dermatology Conference

 in Las Vegas, Shawn Kwatra, MD, professor and chairman of dermatology at the University of Maryland School of Medicine, presented 2 sessions regarding inflammatory skin disease management.

Kwatra spoke in an interview about these 2 presentations, the first of which being titled ‘What’s Itching You Today? Contact Derm? Atopic Derm? What Else?’ Kwatra highlighted some key takeaways in his interview.

The OX40 Ligand Signaling Pathway and Atopic Dermatitis, With Shawn Kwatra, MD

“We talked today about many different case presentations of chronic itch, and we had a few key takeaways and pearls,” Kwatra explained. “One of them was that prurigo nodularis has a very unique morphology. You can have various presentations. You can have nodules, papules, excoriations, or plaques. I presented a few cases of patients who had been mislabeled as having neurotic excoriations, and actually they responded very well to biologic therapy. So [it’s important] to ask about that itch when you have the excavated phenotype.”

Kwatra highlighted other key points in the talk, including a discussion of itch and malignancy. He also discussed chronic pruritus of unknown origin.

“There's an immune subset,” Kwatra said. “They don't have to have these blood biomarkers. And many have high IgE, high blood eosinophils, and we know that there's immune-stimulated pruritus, which is a term our group described where folks, even after Covid vaccine or a PDE1-inhibitor for cancer therapy, develop generalized pruritus that responds to therapies, intramuscular triamcinolone and off-label biologics such as dupilumab.”

Later, Kwatra was asked about his session presentation, titled ‘Exploring the OX40 Ligand Signaling Pathway in Atopic Dermatitis.’

“The way to think about this is that OX40 ligand is the prequel to inflammation,” Kwatra explained. “So we talked about how we see classical cytokines like IL-4, IL-13, IL-31. The question is, how do those cytokines even get there? What is this inflammatory prequel?...There's an epidermal barrier dysfunction in atopic dermatitis, and that allows for antigens to enter the skin, and they actually go to the antigen presenting scale cell, which expresses OX40 ligand interaction with activated T cells.”

Kwatra added that this causes these cytokines to go up and causes T regulatory cells to be suppressed, which he notes are endogenously anti-inflammatory. It also leads to the formation of memory T cells.

“So the thought is that by blocking this ‘inflammatory prequel’ OX40 ligand pathway, you're going to be able to have longer periods of remission to that reduction in memory T cells, and that's what we're seeing,” Kwatra said. “In the STEAM-AD, phase 2b trial, we saw that many of these patients off treatment after 24 weeks maintained response, even after serum levels of the drug had completely diminished and gone away, compared to patients remaining on the drug.”

To find out more about Kwatra’s talk at the Fall Clinical Conference, view the video interview posted above.

Kwatra's disclosures included the following: AbbVie, Arcutis Biotherapeutics, ASLAN Pharmaceuticals, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte, Johnson & Johnson, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi – advisory board member/consultant; Galderma, Incyte, Pfizer, Sanofi – investigator.

Kwatra S. What’s Itching You Today? Contact Derm? Atopic Derm? What Else? Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Kwatra S. Exploring the OX40 Ligand Signaling Pathway in Atopic Dermatitis. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Videos

Kwatra spoke at Fall Clinical about several key highlights from his sessions discussing atopic dermatitis, prurigo nodularis, and the OX40 ligand (OX40L).

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 (FDA) has approved UCB’s doxycitine and doxribtimine (Kygevvi), the first therapy for thymidine kinase 2 deficiency (TK2d), an ultra-rare, inherited mitochondrial disease.

With only 120 reported cases (1.64 per 1,000,000 people), TK2d had no previously approved therapy. The mitochondrial depletion syndrome impairs the body’s ability to produce and repair mitochondrial DNA. Without intervention, the disease impacts an individual’s ability to walk, eat, and breathe independently, significantly impacting patient quality of life.

Doxycitine and doxribtimine is a combined nucleoside therapy. The drug is aimed at supporting mitochondrial DNA replication and stabilizing mitochondrial function in patients. Through the incorporation of nucleosides deoxycytidine and deoxythymidine into skeletal muscle mitochondrial deoxyribonucleic acid, individuals can restore DNA copy and improve skeletal muscle function.

The November 3, 2025, approval was supported by data from a phase 2 clinical study, 2 retrospective reviews, and an expanded access program, including adults and pediatric patients with symptom onset at ≤12 years of age.

In a statement, UCB wrote, “TK2d profoundly affects multiple health, physical, quality-of-life, and psychosocial domains, as children struggle to achieve developmental milestones or lose them, and adults lose functional independence with challenges in breathing, eating, and walking.”

On March 19, 2025, UCB presented the investigative therapy improved survival and functional outcomes, regulated safety, and positive impact on quality of life for individuals and caregivers at the Muscular Dystrophy Association 2025 Conference. The application was granted a priority review, Breakthrough Therapy Designation, and Rare Pediatric Disease Designation.

In a matched survival analysis of 78 pairs of treated and untreated patients, mortality was significantly lower in the doxecitine and doxribtime group. A total of 3 deaths occurred in the patient population receiving doxecitine and doxribtime (4%), and there were 28 deaths in the control group (36%). During a 10-year follow-up, patients mean survival was 9.6 years compared to 5.7 years in the control group.

Patients with TK2d ≤12 years of age saw further improvement in their clinical outcomes and quality of life. In the time from symptom onset to starting  treatment, the risk of death reduced from 92–94% (hazard ratio [HR], 0.06–0.08; 

<.0001). Of the included patients 75% (30/40) regained ≥1 lost motor milestone, and 22.5% (9/40) regained ≥4 motor milestones.

Center. FDA approves 1st drug for thymidine kinase 2 deficiency. U.S. Food and Drug Administration. Published 2025. Accessed November 3, 2025. 

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-thymidine-kinase-2-deficiency-very-rare-mitochondrial-disease

New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference | UCB. Ucb-usa.com. Published March 19, 2025. Accessed November 3, 2025. 

https://www.ucb-usa.com/stories-media/UCB-U-S-News/detail/article/new-data-on-investigational-therapy-for-thymidine-kinase-2-deficiency-presented-at-muscular-dystrophy-association-mda-2025-conference

The FDA has approved UCB's Kygevvi, a groundbreaking therapy for thymidine kinase 2 deficiency (TK2d), a rare mitochondrial disease. TK2d, affecting only 120 reported cases globally, previously lacked approved treatments. Kygevvi, a nucleoside therapy, aids mitochondrial DNA replication, improving patient mobility and quality of life. The approval followed promising results from clinical studies, showing enhanced survival and functional outcomes. The therapy received priority review and special designations due to its significant impact on survival rates and quality of life, particularly in patients with early symptom onset.

The FDA has approved Kygevvi (doxycitine and doxribtimine), the first therapy to improve functional outcomes and survival in thymidine kinase 2 deficiency.

FDA News

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA Approves Kygevvi, First Treatment for Thymidine Kinase 2 Deficiency

Bob Jahr, CEO of Outlook Therapeutics | Image Credit: Vision Monday

Outlook Therapeutics has resubmitted its Biologics License Application (BLA) to the 

 for ONS-5010, an ophthalmic formulation of bevacizumab for the treatment of 

wet age-related macular degeneration (AMD)

Announced on November 3, 2025, this resubmission follows the receipt of official minutes from an FDA Type A meeting, which was completed on September 29, 2025. If approved, ONS-5010 will be branded as LYTENAVA (bevacizumab-vikg) and will become the first approved ophthalmic formulation of bevacizumab for retinal indications, including wet AMD.

“The resubmission of our BLA for ONS-5010 marks an important step forward in our mission to deliver a safe and effective ophthalmic bevacizumab for the treatment of wet AMD in the United States,” Bob Jahr, chief executive officer of Outlook Therapeutics, said in a statement. “Based on our productive meeting with the FDA in September, we believe this resubmission will resolve the outstanding issue highlighted in the Complete Response Letter (CRL) we received in August 2025.”

ONS-5010 is a recombinant humanized monoclonal antibody which selectively binds to all isoforms of VEGF and neutralizes its biologic activity through a steric blocking of VEGF’s binding to its Fit-1 and KDR receptors. After intravitreal injection, this binding to VEGF prevents its interaction with its receptors on the surface of endothelial cells, which reduces proliferation, vascular leakage, and new blood vessel formation in the retina.

Outlook Therapeutics’ last submission of ONS-5010 for regulatory approval was on February 28, 2025, following results from the NORSE EIGHT trial and additional chemistry, manufacturing, and controls (CMC) data requested by the FDA. This was a randomized, controlled, parallel-group, masked, non-inferiority study which enrolled 400 newly diagnosed patients with wet AMD. Investigators randomly assigned these participants in a 1:1 ratio to either 1.25 mg ONS-5010 or 0.5 mg ranibizumab intravitreal injections, which were received at day 0, week 4, and week 8 visits.

Ultimately, ONS-5010 showed clinically meaningful anatomic and functional improvements across all timepoints. Best-corrected visual acuity (BCVA) data also demonstrated an improvement in vision which increased over time. The data set also highlighted a similar anatomical response between treatments, with a reduction in central retinal thickness -123.9 microns for the ONS-5010 arm and -127.3 microns for the ranibizumab group.

However, investigators reported a mean 4.2 letter improvement in BCVA among patients treated with ONS-5010, which did not meet the prespecified non-inferiority endpoint at week 8. Given the endpoint was set forth by agreement with the FDA, Outlook Therapeutics received a CRL noting a lack of substantial evidence of effectiveness. After this decision, Outlook Therapeutics requested the Type A meeting which led to this current resubmission.

ONS-5010 has already been approved by the European Commission and has received MHRA Marketing Authorization for wet AMD treatment and has launched commercially in both Germany and the UK.

Outlook Therapeutics. Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010. November 3, 2025. Accessed November 3, 2025. 

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-re-submits-biologics-license-application

Outlook Therapeutics. Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the US Food and Drug Administration. February 28, 2025. Accessed November 3, 2025. 

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeuticsr-re-submits-biologics-license-application-0

Outlook Therapeutics. Outlook Therapeutics Provides Regulatory Updates on US Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD. August 28, 2025. Accessed November 3, 2025. 

https://ir.outlooktherapeutics.com/news-releases/news-release-details/outlook-therapeutics-provides-regulatory-update-us-food-and-drug

Outlook Therapeutics has resubmitted its Biologics License Application to the FDA for ONS-5010, an ophthalmic bevacizumab formulation for wet AMD. This follows a Type A meeting with the FDA, aiming to address issues from a previous Complete Response Letter. ONS-5010, a VEGF inhibitor, demonstrated clinically meaningful improvements in a trial but did not meet the non-inferiority endpoint. Despite this, it has been approved in Europe and the UK. If approved in the US, it will be branded as LYTENAVA, marking a significant milestone for retinal treatments.

Following a Type A meeting with the FDA, the ophthalmic formulation of bevacizumab is back on track towards a potential US approval.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 for Wet AMD

 in Las Vegas, Nevada, Raj Chovatiya, MD, PhD, co-presented a session titled ‘Seminar-in-Depth: Shifting the Management Paradigm in Generalized Pustular Psoriasis.’

Chovatiya, who currently serves as both clinical associate professor at Rosalind Franklin University Chicago Medical School and director of the Center for Medical Dermatology and Immunology Research, spoke with the team at 

 on his portion of this session. Chovatiya highlighted several key points about managing generalized pustular psoriasis (GPP).

Tips on Addressing Generalized Pustular Psoriasis, With Raj Chovatiya, MD, PhD

“Generalized pustular psoriasis is a pretty rare disease in the dermatology space,” Chovatiya explained. “It's not something that you're going to see perhaps that often in your career, but when you do, it can really be a emergency, from dermatologic perspective. We don't have that many dermatologic conditions where I truly use that word emergency.”

Among patients with GPP, Chovatiya noted, there is a major burden in terms of uncertainty about the course of this skin disease as well as potential for the inpatient hospitalization route, the emergency care route, and even mortality. Chovatiya noted that it is important to know how to diagnose GPP.

“You don't have to have chronic plaque psoriasis to have generalized pustular psoriasis,” Chovatiya said. “It really is a diagnosis that you can make clinically based on the presence of innumerable pustular lesions, usually on an erythematous base on the skin. Typically, there's an onset of symptoms that's highly rapid. There's often a lot of pain…or discomfort that patients experience. And systemic symptoms are another thing that oftentimes accompany this disease, in terms of fever, myalgia, and chills that you just don't see with chronic plaque psoriasis.”

Chovatiya later highlighted GPP’s more homogenous pathway of immunology than had once been thought.

“A lot of the disease itself is mediated by IL-36 and neutrophilic inflammation that is related to IL-36,” Chovatiya said. “it's a very cool story in medicine, how we discovered this as really, once upon a time, it was actually cohorts of consanguineous patients that had similar mutations in this pathway that had a phenotype that we now call GPP. So that's where part three of the talk comes in…where we learned that, actually, blockade of IL-36 signaling can make a huge difference in patients.”

For any additional information on Chovatiya’s talk held at the Fall Clinical Conference, view more by watching his video posted above.

Chovatiya previously reported serving as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Chovatiya R, Elewski B. Seminar-in-Depth: Shifting the Management Paradigm in Generalized Pustular Psoriasis. Session presentation at the 2025 Fall Clinical Dermatology Conference, Las Vegas, Nevada, Oct 23-26, 2025.

Hawkes JE, Visvanathan S, Krueger JG. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Front Immunol. 2023 Nov 21;14:1292941. 

In his Fall Clinical interview, Chovatiya highlights several key takeaways from his talk on generalized pustular psoriasis (GPP) management.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Lindsay Ackerman, MD, highlights clinical strategies for addressing psoriasis in challenging or visible areas such as the scalp, nails, and genitals.

Selecting Psoriasis Therapies for Treatment of High-Impact Areas

Lindsay Ackerman, MD, outlines how clinicians balance efficacy, tolerability, and patient preference when initiating first-line therapy.

Weighing Benefits, Safety Profiles for First-Line Psoriasis Therapies

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

C3 Glomerulopathy

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

Chronic Kidney Disease

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

ASN Kidney Week 2025 Preview: 5 Phase 3 Trials to Know

Susan Corbridge, PhD, and Alanna Kavannagh, MSN, CCRN, discuss the role of advanced practice providers on the evolving pulmonary and critical care teams during CHEST 2025.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Advancing NP and PA Involvement in Pulmonary Care, CHEST Learning

Following CHEST 2025, Hanania discusses the progress being made toward more tailored, patient-oriented care in airway disorders.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

High and Low Temperature Exposure May Influence Cardiovascular Disease Mortality

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

Risankizumab Effective as Treatment for Psoriasis in Genital, Scalp Regions

Gabryszewski said new data confirm early introduction guidelines are working, showing real-world declines in peanut allergy. 

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

Peanut Allergy Decline Shows Success of Early Introduction Guidelines, With Stanislaw J. Gabryszewski, MD, PhD

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 10/26

Recent research has highlighted the influence of minor beat-to-beat changes in blood pressure on the left side of the brain.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Latest News

Depressive Symptoms May Be Associated with Diabetes and Dyslipidemia

The OX40 Ligand Signaling Pathway and Atopic Dermatitis, With Shawn Kwatra, MD

FDA Approves Kygevvi, First Treatment for Thymidine Kinase 2 Deficiency

Outlook Therapeutics Resubmits Biologics License Application for ONS-5010 for Wet AMD

Tips on Addressing Generalized Pustular Psoriasis, With Raj Chovatiya, MD, PhD